General Information of Drug (ID: DMYNTQV)

Drug Name
CGP-28014 Drug Info
Synonyms
Cgp 28014; 111757-17-6; Methanimidamide, N'-(1,6-dihydro-6-oxo-2-pyridinyl)-N,N-dipropyl-; N-(2-Oxopyridin-6-yl)-N',N'-di-n-propylformamidine; N'-(1,6-Dihydro-6-oxo-2-pyridinyl)-N,N-dipropylmethanimidamide; CGP-28014; N-(2-pyridone-6-yl)-N',N'-di-n-propylformamidine; cgp28014; CHEBI:79969; LS-90457
Indication
Disease Entry ICD 11 Status REF
Major depressive disorder 6A70.3 Phase 2 [1]
Cross-matching ID
PubChem CID
159470
CAS Number
CAS 111757-17-6
TTD Drug ID
DMYNTQV

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Preclinical Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Entacapone DMLBVKQ Parkinson disease 8A00.0 Approved [2]
Opicapone DM1BKA6 Parkinson disease 8A00.0 Approved [3]
Tolcapone DM8MNVO Parkinson disease 8A00.0 Approved [4]
BIA 3-202 DMG3ON2 Parkinson disease 8A00.0 Phase 2 [5]
Nitecapone DMSJYEX Pain MG30-MG3Z Discontinued in Phase 2 [6]
PGX-200097 DM1A2UI Schizophrenia 6A20 Preclinical [7]
1-(3,4-dihydroxy-5-nitrophenyl)-2-phenoxyethanone DMKI719 Discovery agent N.A. Investigative [8]
7,8-dihydroxy-4-phenyl-2H-chromen-2-one DMUB5E8 Discovery agent N.A. Investigative [9]
3,5-Dinitrocatechol DMBGSHD Discovery agent N.A. Investigative [10]
1-(3,4-dihydroxy-2-nitrophenyl)-2-phenylethanone DM9M5D1 Discovery agent N.A. Investigative [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Catechol-O-methyl-transferase (COMT) TTKWFB8 COMT_HUMAN Modulator [1]

References

1 CGP 28014, a new inhibitor of cerebral catechol-O-methylation with a non-catechol structure. Naunyn Schmiedebergs Arch Pharmacol. 1990 Sep;342(3):305-11.
2 Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease. Clin Ther. 2001 Jun;23(6):802-32; discussion 771.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
4 Catechol-O-methyltransferase inhibitors in the management of Parkinson's disease. Semin Neurol. 2001;21(1):15-22.
5 Chemical synthesis and characterization of conjugates of a novel catechol-O-methyltransferase inhibitor. Bioconjug Chem. 2002 Sep-Oct;13(5):1112-8.
6 Effect of a novel catechol-O-methyltransferase inhibitor, nitecapone, on the metabolism of L-dopa in healthy volunteers. Clin Neuropharmacol. 1990 Oct;13(5):436-47.
7 Schizophrenia, "just the facts" 5. Treatment and prevention. Past, present, and future. Schizophr Res. 2010 Sep;122(1-3):1-23.
8 Synthesis, biological evaluation, and molecular modeling studies of a novel, peripherally selective inhibitor of catechol-O-methyltransferase. J Med Chem. 2004 Dec 2;47(25):6207-17.
9 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
10 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
11 Synthesis and biological evaluation of a novel series of "ortho-nitrated" inhibitors of catechol-O-methyltransferase. J Med Chem. 2005 Dec 15;48(25):8070-8.